Foracort Nebulisation and Serum Potassium
Foracort nebulisation can alter serum potassium levels, specifically causing hypokalemia (low potassium), primarily due to its formoterol (beta-2 agonist) component rather than the beclomethasone component.
Mechanism and Evidence
The potassium-lowering effect is a well-established pharmacological action of beta-2 agonists like formoterol, which is one of the active ingredients in Foracort. Beta-agonist medications produce hypokalemia through intracellular shunting of potassium, which has the potential to produce adverse cardiovascular effects 1.
Formoterol-Specific Effects
The FDA drug label for formoterol (the beta-2 agonist in Foracort) explicitly states that decreases in plasma potassium are among the most common adverse effects 1. In pharmacokinetic/pharmacodynamic studies:
- Following inhalation of formoterol 120 mcg (10 times the recommended dose), reductions of plasma potassium concentration were observed in all subjects
- Maximum reductions ranged from 0.55 to 1.52 mmol/L with a median reduction of 1.01 mmol/L
- There was a linear relationship between formoterol exposure and decreases in serum potassium 1
- The maximum effect on plasma potassium typically occurred 1-3 hours after peak formoterol concentrations
Beclomethasone Component
In contrast, beclomethasone dipropionate (the corticosteroid component) does not significantly alter serum potassium levels. Multiple studies confirm this:
- A comparative study showed that while fenoterol (a beta-2 agonist) caused significant decreases in plasma potassium, beclomethasone treatment did not produce significant changes in potassium levels 2
- A pediatric study found that treatment with beclomethasone alone or combined with salmeterol for 6 weeks did not alter serum potassium 3
Clinical Implications and Monitoring
The decrease in serum potassium is usually transient and does not require supplementation in most cases 1. However, monitoring is essential because:
- Even modest decreases in serum potassium can increase risks when using digitalis and antiarrhythmic drugs 4, 5
- Hypokalemia may adversely affect cardiac excitability and conduction, potentially leading to serious arrhythmias 4, 5
Monitoring Recommendations
Serum potassium should be monitored periodically in patients receiving beta-2 agonists, particularly in those with:
- Cardiovascular disease
- Concurrent use of diuretics (which can also cause hypokalemia) 6, 7
- Concurrent use of medications affecting potassium balance
- Renal impairment
The effect is dose-dependent, with higher doses producing more pronounced potassium reduction 1. At recommended therapeutic doses of Foracort, clinically significant changes in serum potassium are infrequent but possible 1.
Important Caveats
- The potassium-lowering effect is primarily a concern with the formoterol component, not the beclomethasone
- This is a class effect of all beta-2 agonists, not unique to Foracort
- The effect is generally transient and well-tolerated at therapeutic doses
- Concurrent diuretic use increases the risk of clinically significant hypokalemia and requires closer monitoring 6